115 studies found for:    myeloma and velcade | Open Studies
Show Display Options
Rank Status Study
1 Unknown  VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
Condition: Multiple Myeloma
Intervention: Drug: bortezomib
2 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
3 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
4 Recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
5 Not yet recruiting A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Condition: Multiple Myeloma
Interventions: Drug: Revlimid;   Drug: Velcade;   Drug: dexamethasone;   Drug: Farydak
6 Recruiting A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib
7 Recruiting Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Condition: Multiple Myeloma
Interventions: Drug: Melphalan;   Drug: Bortezomib
8 Recruiting Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
Conditions: Multiple Myeloma;   High-Risk Cancer
Intervention: Drug: Bortezomib following nonmyeloablative allogeneic transplant
9 Recruiting Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Mozobil
10 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
11 Recruiting A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: JNJ-54767414 (Daratumumab);   Drug: Bortezomib;   Drug: Dexamethasone
12 Recruiting Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine, Bortezomib, Prednisone
13 Not yet recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
14 Recruiting Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Auto Stem Cell Transplant
Intervention: Drug: Bortezomib
15 Recruiting Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Biological: Elotuzumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
16 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
17 Unknown  Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
18 Not yet recruiting Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat Velcade Dexamethasone
19 Recruiting Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Bortezomib;   Drug: G-CSF
20 Recruiting Optimising Renal Outcome in Myeloma Renal Failure
Conditions: Multiple Myeloma;   Chronic Kidney Disease
Interventions: Drug: Bortezomib;   Drug: Thalidomide;   Drug: Bendamustine;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years